Christophe Lahorte

Dr. Christophe Lahorte holds a master degree in pharmaceutical sciences and has performed academic research for 6 years at the Gent University (Faculty of Pharmacy, Laboratory of Radiopharmacy) where he was responsible for the chemical-pharmaceutical and preclinical development of new radiopharmaceuticals in collaboration with the Nuclear Medicine Dept. of the University hospital Gent (UZG).

He obtained a PhD in Pharmaceutical Sciences at the University of Gent in 2004 after which he moved to the Federal Public Health services as a quality assessor. At that time Dr. Lahorte was temporarily member of the CHMP Quality Working Party et the European Medicines Agency (EMA).

Since september 2004 he has been actively involved within the R&D department of the Federal Agency of Medicines and Health Products (FAMHP) in the quality assessment of clinical trial applications (CTA’s) and paediatric investigation plans (PIP’s). Since 2006 he has also been involved in the assessment of several national and European scientific advice requests.

In May 2009 Dr. Lahorte was appointed as head of the FAMHP’s Unit for National Scientific-Technical Advice & Knowledge Management within the Directorate General pre authorisation. In May 2017 Dr. Lahorte became the Head of the FAMHP’s National Innovation Office which aims to support and guide all types of innovators (eg. spin-offs, SME’ and global companies, academia etc) developing new innovative drug products and medical technologies in Belgium and Europe.

In addition, Dr. Lahorte is actively involved in several European projects coordinated by the EMA and European Commission including the “Accelerating Clinical Trials in the EU (ACT EU) - Delivering an EU clinical trials transformation initiative”.